Since December 2019, the world was encountered a new disease called coronavirus
disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 …

Pharmacotherapy, in many cases, is practiced at a suboptimal level of performance in low‐
and middle‐income countries (LMICs) although stupendous amounts of data are available …

Introduction Health care workers are at high risk of being infected with the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and …

The environmental release of antimicrobial pharmaceuticals is an imminent threat due to
ecological impacts and microbial resistance phenomena. The recent COVID-19 outbreak …

Background Hydroxychloroquine has shown potential to block viral replication of SARS-CoV-
2 in some in vitro studies. This randomised, double-blinded, placebo controlled clinical trial …

Abstract Remdesivir (RDV, Veklury®) is an FDA-approved prodrug for the treatment of
hospitalized patients with COVID-19. Recent in vitro studies have indicated that human …

A global public health crisis caused by the 2019 novel coronavirus disease (COVID-19)
leads to considerable morbidity and mortality, which bring great challenge to respiratory …

Drug-mediated correction of abnormal biological zinc homeostasis could provide new routes
to treating neurodegeneration, cancer, and viral infections. Designing therapeutics to …

Rationale Inhaled antimicrobials enable high local concentrations where needed and,
compared to orally administration, greatly reduce the potential for systemic side effects. In …

Artemisinin-hydroxychloroquine sulfate tablets (AH) are considered a relatively inexpensive
and novel combination therapy for treating all forms of malaria, especially aminoquinoline …